OncoMatch/Clinical Trials/NCT06954961
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
Is NCT06954961 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including D-0502 and Fulvestrant for breast cancer.
Treatment: D-0502 · Fulvestrant — This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative
Required: ESR1 positive
Prior therapy
Must have received: endocrine therapy — adjuvant or metastatic
disease recurrence during or after adjuvant endocrine therapy, or whose disease has progressed after 1-2 lines of systemic endocrine therapy
Cannot have received: systemic chemotherapy
Exception: no more than 2 prior systemic chemotherapy
Subjects with locally advanced or metastatic breast cancer who have previously received more than 2 prior systemic chemotherapy
Cannot have received: selective estrogen receptor degrader (SERD)/selective estrogen receptor covalent antagonist (SERCA) (fulvestrant, GDC-9545, AZD9833, SAR-439859, Zn-c5, LX-039, HS234)
Prior treatment with a selective estrogen receptor degrader (SERD)/selective estrogen receptor covalent antagonist (SERCA), such as fulvestrant, GDC-9545, AZD9833, SAR-439859, Zn -c5, LX-039, HS234, etc.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify